MCID: FLL015
MIFTS: 33

Fallopian Tube Serous Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Fallopian Tube Serous Adenocarcinoma

MalaCards integrated aliases for Fallopian Tube Serous Adenocarcinoma:

Name: Fallopian Tube Serous Adenocarcinoma 12 15 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:5598
NCIt 50 C40099
UMLS 71 C1517124

Summaries for Fallopian Tube Serous Adenocarcinoma

Disease Ontology : 12 A fallopian tube adenocarcinoma that derives from epithelial cells originating in glandular tissue forming serous lesions.

MalaCards based summary : Fallopian Tube Serous Adenocarcinoma is related to serous cystadenocarcinoma and fallopian tube carcinoma. An important gene associated with Fallopian Tube Serous Adenocarcinoma is FZD3 (Frizzled Class Receptor 3), and among its related pathways/superpathways are CDK-mediated phosphorylation and removal of Cdc6 and Signaling by GPCR. The drugs Carboplatin and Letrozole have been mentioned in the context of this disorder. Affiliated tissues include ovary and endothelial, and related phenotypes are craniofacial and digestive/alimentary

Related Diseases for Fallopian Tube Serous Adenocarcinoma

Diseases related to Fallopian Tube Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 13)
# Related Disease Score Top Affiliating Genes
1 serous cystadenocarcinoma 10.3
2 fallopian tube carcinoma 10.1
3 adenocarcinoma 10.1
4 papillary adenocarcinoma 10.1
5 fallopian tube adenocarcinoma 10.1
6 cerebellar degeneration 10.1
7 subacute cerebellar degeneration 10.1
8 brachydactyly, type b1 9.9 WNT5A ROR2
9 autosomal dominant robinow syndrome 9.9 WNT5A ROR2
10 robinow syndrome, autosomal dominant 1 9.7 WNT5A ROR2
11 norrie disease 9.7 WNT5B WNT5A WNT11
12 strabismus 9.6 WNT5A WNT11 FZD3
13 exudative vitreoretinopathy 9.3 WNT5B WNT5A WNT11 FZD3 FZD1

Graphical network of the top 20 diseases related to Fallopian Tube Serous Adenocarcinoma:



Diseases related to Fallopian Tube Serous Adenocarcinoma

Symptoms & Phenotypes for Fallopian Tube Serous Adenocarcinoma

MGI Mouse Phenotypes related to Fallopian Tube Serous Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.55 FZD1 GSK3B ROR2 WNT11 WNT5A
2 digestive/alimentary MP:0005381 9.35 FZD1 GSK3B ROR2 WNT11 WNT5A
3 normal MP:0002873 9.1 FZD1 FZD10 FZD3 GSK3B RHOA WNT5A

Drugs & Therapeutics for Fallopian Tube Serous Adenocarcinoma

Drugs for Fallopian Tube Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
2
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
3
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
4
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
5
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
6
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
7 Aromatase Inhibitors Phase 3
8 Estrogen Antagonists Phase 3
9 Hormone Antagonists Phase 3
10 Albumin-Bound Paclitaxel Phase 3
11 Hormones Phase 3
12 Estrogen Receptor Antagonists Phase 3
13 Estrogens Phase 3
14 Tubulin Modulators Phase 3
15 Antimitotic Agents Phase 3
16 Angiogenesis Inhibitors Phase 2, Phase 3
17 Antineoplastic Agents, Immunological Phase 2, Phase 3
18 Immunoglobulin G Phase 2, Phase 3
19 Antibiotics, Antitubercular Phase 2, Phase 3
20 Immunologic Factors Phase 2, Phase 3
21 Immunoglobulins Phase 2, Phase 3
22 Mitogens Phase 2, Phase 3
23 Anti-Bacterial Agents Phase 2, Phase 3
24 Antibodies, Monoclonal Phase 2, Phase 3
25 Immunoglobulins, Intravenous Phase 2, Phase 3
26 Antibodies Phase 2, Phase 3
27
Liposomal doxorubicin Phase 2, Phase 3 31703
28 Endothelial Growth Factors Phase 2, Phase 3
29
Olaparib Approved Phase 1 763113-22-0 23725625
30 Poly(ADP-ribose) Polymerase Inhibitors Phase 1
31
Talazoparib Approved, Investigational Early Phase 1 1207456-01-6 135565082

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Recruiting NCT04095364 Phase 3 Carboplatin;Letrozole;Paclitaxel
2 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
3 A Phase I/II, Single Center, Proof-of-Concept Study of Birinapant in Combination With Platinum Based Chemotherapy Targeting Recurrent High Grade Serous Ovarian Carcinomas (HGSOC) Withdrawn NCT02756130 Phase 1, Phase 2 Birinapant;Carboplatin
4 A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting NCT02898207 Phase 1 Olaparib;Onalespib
5 POSITION: A Pilot Study of Induction PARP Inhibition in Ovarian Cancer Active, not recruiting NCT02316834 Early Phase 1 BMN 673

Search NIH Clinical Center for Fallopian Tube Serous Adenocarcinoma

Genetic Tests for Fallopian Tube Serous Adenocarcinoma

Anatomical Context for Fallopian Tube Serous Adenocarcinoma

MalaCards organs/tissues related to Fallopian Tube Serous Adenocarcinoma:

40
Ovary, Endothelial

Publications for Fallopian Tube Serous Adenocarcinoma

Articles related to Fallopian Tube Serous Adenocarcinoma:

# Title Authors PMID Year
1
Fallopian tube serous adenocarcinoma with dizziness as the initial symptom: a case report. 61
31500488 2020
2
Spinal Metastases from a Primary Fallopian Tube Serous Adenocarcinoma: A Case Report. 61
26430604 2015
3
Proteomic analyses of serous and endometrioid epithelial ovarian cancers - cases studies - molecular insights of a possible histological etiology of serous ovarian cancer. 61
23589350 2013
4
Left fallopian tube primitive serous adenocarcinoma presenting as a cardiac tamponade - a case report and review of literature. 61
23967559 2013

Variations for Fallopian Tube Serous Adenocarcinoma

Expression for Fallopian Tube Serous Adenocarcinoma

Search GEO for disease gene expression data for Fallopian Tube Serous Adenocarcinoma.

Pathways for Fallopian Tube Serous Adenocarcinoma

Pathways related to Fallopian Tube Serous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 WNT5B WNT5A WNT11 ROR2 RHOA GSK3B
2
Show member pathways
14 WNT5B WNT5A WNT11 ROR2 RHOA GSK3B
3
Show member pathways
13.67 WNT5A ROR2 RHOA GSK3B FZD3 FZD10
4
Show member pathways
13.36 WNT5B WNT5A WNT11 GSK3B FZD3 FZD10
5
Show member pathways
13.25 WNT5B WNT5A WNT11 ROR2 GSK3B FZD3
6
Show member pathways
12.99 WNT5B WNT5A WNT11 GSK3B FZD3 FZD10
7
Show member pathways
12.89 WNT5B WNT5A WNT11 GSK3B FZD3 FZD10
8
Show member pathways
12.89 WNT5B WNT5A WNT11 ROR2 RHOA GSK3B
9 12.82 WNT5B WNT5A WNT11 RHOA GSK3B FZD3
10
Show member pathways
12.77 WNT5B WNT5A WNT11 GSK3B FZD3 FZD10
11
Show member pathways
12.5 WNT5B WNT5A WNT11 GSK3B FZD3 FZD10
12
Show member pathways
12.42 WNT5A WNT11 FZD3 FZD10 FZD1
13
Show member pathways
12.34 WNT5B WNT5A WNT11 GSK3B FZD3 FZD10
14
Show member pathways
12.33 WNT5B WNT5A WNT11 RHOA GSK3B FZD3
15 12.31 WNT5B WNT5A WNT11 RHOA FZD3 FZD10
16 12.28 WNT5B WNT5A RHOA GSK3B FZD3
17 12.17 WNT5B WNT5A GSK3B FZD3 FZD10 FZD1
18 12.17 WNT5B WNT5A WNT11 GSK3B FZD3 FZD10
19 12.16 WNT5B WNT5A WNT11 RHOA GSK3B FZD3
20
Show member pathways
12.14 WNT5A RHOA GSK3B FZD1
21 12.11 WNT5B WNT5A GSK3B
22 12.11 WNT5B WNT5A WNT11 GSK3B FZD3 FZD10
23 12.09 RHOA FZD10 FZD1
24 12.09 RHOA GSK3B FZD3 FZD10 FZD1
25 12.05 WNT5B WNT5A WNT11 RHOA GSK3B
26 12.03 RHOA GSK3B FZD3 FZD10 FZD1
27 12.02 WNT5B WNT5A WNT11 GSK3B FZD3 FZD10
28 11.94 GSK3B FZD3 FZD10 FZD1
29
Show member pathways
11.86 WNT5B WNT5A WNT11 ROR2 RHOA GSK3B
30 11.74 WNT11 RHOA GSK3B FZD3 FZD10 FZD1
31
Show member pathways
11.69 WNT5B WNT5A WNT11 GSK3B FZD1
32 11.55 ROR2 RHOA GSK3B
33 11.48 WNT5B WNT5A WNT11 ROR2 RHOA GSK3B
34 11.34 GSK3B FZD1
35 11.32 WNT5A ROR2 FZD10 FZD1
36 11.28 WNT5A ROR2 RHOA
37 10.92 GSK3B FZD1

GO Terms for Fallopian Tube Serous Adenocarcinoma

Cellular components related to Fallopian Tube Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.62 ROR2 RHOA GSK3B FZD3
2 plasma membrane GO:0005886 9.61 WNT5B WNT5A ROR2 RHOA GSK3B FZD3
3 postsynapse GO:0098794 9.43 WNT5A RHOA GSK3B
4 clathrin-coated endocytic vesicle membrane GO:0030669 9.37 WNT5A ROR2
5 Wnt signalosome GO:1990909 9.16 GSK3B FZD1
6 cell surface GO:0009986 9.1 WNT5A ROR2 FZD3 FZD10 FZD1 CEACAM5

Biological processes related to Fallopian Tube Serous Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 10.07 WNT5A WNT11 ROR2 RHOA GSK3B
2 positive regulation of transcription, DNA-templated GO:0045893 10 WNT5A WNT11 ROR2 FZD1
3 protein phosphorylation GO:0006468 9.99 WNT5A WNT11 ROR2 GSK3B
4 negative regulation of apoptotic process GO:0043066 9.99 WNT5A WNT11 GSK3B CEACAM5
5 multicellular organism development GO:0007275 9.97 WNT5B WNT5A WNT11 ROR2 GSK3B FZD3
6 positive regulation of GTPase activity GO:0043547 9.94 WNT5A WNT11 GSK3B FZD10
7 positive regulation of cell migration GO:0030335 9.91 WNT5B WNT11 ROR2 RHOA
8 response to drug GO:0042493 9.89 RHOA FZD3 FZD1
9 positive regulation of neuron projection development GO:0010976 9.84 WNT5A ROR2 FZD1
10 negative regulation of canonical Wnt signaling pathway GO:0090090 9.81 WNT5A WNT11 ROR2 GSK3B
11 neuron differentiation GO:0030182 9.8 WNT5B WNT5A WNT11 FZD3 FZD10 FZD1
12 inner ear morphogenesis GO:0042472 9.76 WNT5A ROR2 FZD3
13 cell fate commitment GO:0045165 9.76 WNT5B WNT5A WNT11 ROR2
14 epithelial to mesenchymal transition GO:0001837 9.73 WNT5A WNT11 GSK3B
15 cellular response to retinoic acid GO:0071300 9.73 WNT5B WNT5A WNT11 FZD10
16 Wnt signaling pathway, planar cell polarity pathway GO:0060071 9.73 WNT5A WNT11 ROR2 RHOA FZD3 FZD1
17 somitogenesis GO:0001756 9.71 WNT5A ROR2
18 bone mineralization GO:0030282 9.71 WNT11 ROR2
19 positive regulation of neuron death GO:1901216 9.71 WNT5A GSK3B
20 negative chemotaxis GO:0050919 9.71 WNT5A RHOA
21 Wnt signaling pathway, calcium modulating pathway GO:0007223 9.71 WNT5A WNT11 ROR2 FZD3
22 regulation of neuron projection development GO:0010975 9.7 RHOA GSK3B
23 embryonic skeletal system development GO:0048706 9.7 WNT5A WNT11
24 ventricular septum development GO:0003281 9.7 WNT5A WNT11
25 regulation of microtubule cytoskeleton organization GO:0070507 9.69 RHOA GSK3B
26 midbrain development GO:0030901 9.69 WNT5A FZD3
27 beta-catenin destruction complex disassembly GO:1904886 9.68 GSK3B FZD1
28 establishment of epithelial cell apical/basal polarity GO:0045198 9.68 WNT5A RHOA
29 somite development GO:0061053 9.68 WNT5A WNT11
30 post-anal tail morphogenesis GO:0036342 9.67 WNT5A FZD3
31 establishment of planar polarity GO:0001736 9.67 WNT5A FZD3
32 presynapse assembly GO:0099054 9.66 WNT5A FZD1
33 secondary palate development GO:0062009 9.65 WNT5A WNT11
34 secondary heart field specification GO:0003139 9.65 WNT5A WNT11
35 positive regulation of protein kinase C signaling GO:0090037 9.65 WNT5A WNT11
36 positive regulation of JUN kinase activity GO:0043507 9.65 WNT5A ROR2 FZD10
37 atrial septum development GO:0003283 9.64 WNT5A WNT11
38 positive regulation of non-canonical Wnt signaling pathway GO:2000052 9.63 WNT5B WNT5A
39 positive regulation of protein kinase C activity GO:1900020 9.63 WNT5A ROR2
40 paraxial mesoderm formation GO:0048341 9.62 WNT5A WNT11
41 Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation GO:1904953 9.62 WNT5A FZD1
42 negative regulation of mesenchymal cell proliferation GO:0072201 9.61 WNT5A WNT11
43 notochord morphogenesis GO:0048570 9.6 WNT5A WNT11
44 non-canonical Wnt signaling pathway via JNK cascade GO:0038031 9.59 WNT5A FZD10
45 positive regulation of heart induction by negative regulation of canonical Wnt signaling pathway GO:0090082 9.58 WNT5A WNT11
46 convergent extension involved in axis elongation GO:0060028 9.57 WNT5A WNT11
47 planar cell polarity pathway involved in axon guidance GO:1904938 9.55 WNT5A FZD3
48 non-canonical Wnt signaling pathway GO:0035567 9.55 WNT5A WNT11 FZD3 FZD10 FZD1
49 planar cell polarity pathway involved in axis elongation GO:0003402 9.54 WNT5A WNT11
50 primary heart field specification GO:0003138 9.52 WNT5A WNT11

Molecular functions related to Fallopian Tube Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.56 WNT5B WNT5A WNT11 FZD1
2 transmembrane signaling receptor activity GO:0004888 9.54 FZD3 FZD10 FZD1
3 cytokine activity GO:0005125 9.5 WNT5B WNT5A WNT11
4 Wnt-activated receptor activity GO:0042813 9.33 FZD3 FZD10 FZD1
5 Wnt-protein binding GO:0017147 9.26 ROR2 FZD3 FZD10 FZD1
6 frizzled binding GO:0005109 9.02 WNT5B WNT5A WNT11 ROR2 FZD1

Sources for Fallopian Tube Serous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....